BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Idiopathic Hypersomnia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Idiopathic Hypersomni
 a\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06843590-10854@assetmemo.bio
DTSTAMP:20261121T005421Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alixorexton: Phase 2 readout est. (NCT06843590)
DESCRIPTION:Alixorexton\, phase 2\, Idiopathic Hypersomnia.\nStudy: A Study
  to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Id
 iopathic Hypersomnia\nEstimated primary completion: November 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alixorexton#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06843590
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625280-11034@assetmemo.bio
DTSTAMP:20261121T005421Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:Calcium\, magnesium\, potassium and sodium oxybates (Xywav): Phase 
 3 readout est. (NCT07625280)
DESCRIPTION:Calcium\, magnesium\, potassium and sodium oxybates (Xywav)\, p
 hase 3\, Narcolepsy.\nStudy: A Study Evaluating the Efficacy and Safety of
  Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH\nE
 stimated primary completion: 23 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxybates-
 xywav#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07625280
URL:https://assetmemo.bio/drug/calcium-magnesium-potassium-and-sodium-oxyba
 tes-xywav#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767683-10854@assetmemo.bio
DTSTAMP:20261121T005421Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Alixorexton: Phase 2/3 readout est. (NCT06767683)
DESCRIPTION:Alixorexton\, phase 2/3\, Narcolepsy.\nStudy: A Long-Term Study
  of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia\nEsti
 mated primary completion: June 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/alixorexton#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06767683
URL:https://assetmemo.bio/drug/alixorexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
